These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39133308)

  • 1. Assessing low-dose oral minoxidil efficacy in androgenetic alopecia: a comparative study of AGA and AGA unmasked by telogen effluvium.
    Desai DD; Nohria A; Sikora M; Anyanwu N; Shapiro J; Lo Sicco KI
    Arch Dermatol Res; 2024 Aug; 316(8):514. PubMed ID: 39133308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral minoxidil use in androgenetic alopecia and telogen effluvium.
    Feaster B; Onamusi T; Cooley JE; McMichael AJ
    Arch Dermatol Res; 2023 Mar; 315(2):201-205. PubMed ID: 35244759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia.
    Gupta AK; Talukder M; Shemer A
    Expert Opin Pharmacother; 2024 Feb; 25(2):139-147. PubMed ID: 38315101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia.
    Cedirian S; Bruni F; Quadrelli F; Caro G; Fortuna M; Rossi A; Piraccini BM; Starace M
    J Cosmet Dermatol; 2023 Dec; 22(12):3347-3351. PubMed ID: 37415302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral minoxidil treatment for hair loss: A review of efficacy and safety.
    Randolph M; Tosti A
    J Am Acad Dermatol; 2021 Mar; 84(3):737-746. PubMed ID: 32622136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgenetic alopecia: an evidence-based treatment update.
    Varothai S; Bergfeld WF
    Am J Clin Dermatol; 2014 Jul; 15(3):217-30. PubMed ID: 24848508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
    Vañó-Galván S; Pirmez R; Hermosa-Gelbard A; Moreno-Arrones ÓM; Saceda-Corralo D; Rodrigues-Barata R; Jimenez-Cauhe J; Koh WL; Poa JE; Jerjen R; Trindade de Carvalho L; John JM; Salas-Callo CI; Vincenzi C; Yin L; Lo-Sicco K; Waskiel-Burnat A; Starace M; Zamorano JL; Jaén-Olasolo P; Piraccini BM; Rudnicka L; Shapiro J; Tosti A; Sinclair R; Bhoyrul B
    J Am Acad Dermatol; 2021 Jun; 84(6):1644-1651. PubMed ID: 33639244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review.
    Gupta AK; Talukder M; Shemer A; Piraccini BM; Tosti A
    Skin Appendage Disord; 2023 Dec; 9(6):423-437. PubMed ID: 38376087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial.
    Penha MA; Miot HA; Kasprzak M; Müller Ramos P
    JAMA Dermatol; 2024 Jun; 160(6):600-605. PubMed ID: 38598226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minoxidil: a comprehensive review.
    Gupta AK; Talukder M; Venkataraman M; Bamimore MA
    J Dermatolog Treat; 2022 Jun; 33(4):1896-1906. PubMed ID: 34159872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the efficacy and quality of Life improvements of botulinum toxin type a with topical minoxidil versus topical minoxidil in male androgenetic alopecia: a randomized controlled trial.
    Yu L; Moorthy S; Li X; Peng L; Zhang Z; Shen L; Han Y; Huang X
    Arch Dermatol Res; 2024 Aug; 316(8):532. PubMed ID: 39154106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.
    Arca E; Açikgöz G; Taştan HB; Köse O; Kurumlu Z
    Dermatology; 2004; 209(2):117-25. PubMed ID: 15316165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Evaluation of the Clinical Efficacy of PRP-Therapy, Minoxidil, and Their Combination with Immunohistochemical Study of the Dynamics of Cell Proliferation in the Treatment of Men with Androgenetic Alopecia.
    Pakhomova EE; Smirnova IO
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigator-blinded, controlled, and randomized comparative study on 1565 nm non-ablative fractional laser versus 5% minoxidil for treatment of androgenetic alopecia.
    Qu H; Zhang R; Xin W; Jing H; Wang G; Gao L
    J Cosmet Dermatol; 2024 May; 23(5):1638-1644. PubMed ID: 38247260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study.
    de Nicolas-Ruanes B; Moreno-Arrones OM; Saceda-Corralo D; Hermosa-Gelbard A; Rodrigues-Barata R; Gil-Redondo R; Garcia-Mouronte E; Vañó-Galván S
    J Am Acad Dermatol; 2022 Sep; 87(3):700-702. PubMed ID: 35476919
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study.
    Blume-Peytavi U; Issiakhem Z; Gautier S; Kottner J; Wigger-Alberti W; Fischer T; Hoffmann R; Tonner F; Bouroubi A; Voisard JJ
    J Cosmet Dermatol; 2019 Feb; 18(1):215-220. PubMed ID: 29659116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
    Suchonwanit P; Rojhirunsakool S; Khunkhet S
    Lasers Med Sci; 2019 Dec; 34(9):1857-1864. PubMed ID: 30982177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A prospective, randomized, 3-month, controlled, assessor-blinded study.
    Milani M; Colombo F;
    Skin Res Technol; 2023 Jun; 29(6):e13381. PubMed ID: 37357646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-ablative Er:YAG laser is an effective tool in the treatment arsenal of androgenetic alopecia.
    Day D; McCarthy M; Talaber I
    J Cosmet Dermatol; 2022 May; 21(5):2056-2063. PubMed ID: 34435735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red LED light therapy for telogen effluvium in the course of long COVID in patients with and without androgenetic alopecia.
    Gerkowicz A; Bartosińska J; Krakowski P; Karpiński R; Krasowska D; Raczkiewicz D; Kwasny M; Krasowska D
    Ann Agric Environ Med; 2024 Jun; 31(2):239-247. PubMed ID: 38940108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.